The QualityStocks Daily Thursday, September 5th, 2019

Today's Top 3 Investment Newsletters

StocksToBuyNow (GNAL) +61.29%

NetworkNewsWire (RNWR) +58.33%

StockMarketWatch (EDSA) +45.13%

The QualityStocks Daily Stock List

Tremor International Ltd. (TTTPF)

Stock Market Watch, Nasdaq, Morningstar, GuruFocus, Market Screener, Stockhouse, and Seeking Alpha reported earlier on Tremor International Ltd. (TTTPF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Tremor International Ltd. is a global leader in advertising technologies. The Company has operations in over 60 countries. It works with greater than 450 advertisers and more than 50,000 supply and publishing partners around the world. Tremor International lists on the OTC Markets. Established in 2007, the Company has its corporate headquarters in Tel Aviv, Israel.

The Company previously went by the name Taptica International Ltd. It changed its name to Tremor International Ltd. in June of this year.

Tremor International mainly serves companies and brands in Israel, the U.S., China, Germany, Korea, Japan, India, the United Kingdom (UK), and internationally. Together with its subsidiaries, the Company provides performance-based mobile marketing and brand advertising services.

Tremor International’s business divisions are Tremor Video, RhythmOne, and Taptica. Tremor Video is one of the largest video advertising companies. It has market-leading Connected TV and second-screen device solutions. Tremor Video helps advertisers deliver the most engaging brand stories in a complex video landscape.

Tremor International’s RhythmOne division is a market leader in multiscreen digital advertising solutions. RhythmOne is led by advanced TV and powered by one of the most efficient and effective programmatic platforms. It provides unique solutions for brands to connect with consumers.

Tremor International sees value in U.S.-based internet TV provider YuMe, owned by RhythmOne, working alongside the Company’s Tremor Video, a platform that matches advertisers with their desired audiences. Tremor International bought Tremor Video's Demand-Side Platform to push into the United States and Japan-based Adinnovation.

Taptica is an end-to-end mobile advertising platform. Taptica helps the world’s foremost brands reach their most valuable users with the broadest range of traffic sources available. Taptica’s proprietary technology takes advantage of big data to enable quality media targeting at scale.

Fundamentally, Tremor International offers digital advertising solutions leveraging the latest video, native, and display technology to reach the most valuable users for every application (app), service, and brand. The advertisers that the Company works with includes Amazon, Disney, Twitter, OpenTable, Expedia, and Zynga.

Tremor International Ltd. (TTTPF), closed Thursday's trading session at $1.80, up 12.50%, on 21,306 volume with 3 trades. The average volume for the last 3 months is 2,969 and the stock's 52-week low/high is $0.000199999/$4.22249984.

chart

CCUR Holdings, Inc. (CCUR)

Stock Twits, Zacks, Vintage Value Investing, Simply Wall St, Market Screener, Stockhouse, The Street, Stockwatch, Last10k, InvestorsHub, Stocksholm, Pitch Book, Seeking Alpha, Insider Tracking, 4-Traders, YCharts, Value Walk, TipRanks, MarketWatch, and Equity Clock reported beforehand on CCUR Holdings, Inc. (CCUR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CCUR Holdings, Inc., (previously known as Concurrent Computer Corporation), changed its name in January of 2018 following the sale of its former Real-Time business to Battery Ventures in May of 2017 and Content Delivery & Storage business in December of 2017. CCUR Holdings is presently pursuing business opportunities to maximize the value of its assets through evaluation of additional operating businesses or assets for acquisition, continued development of its current real estate operations through its subsidiary Recur Holdings LLC, and continued development of its MCA business operations via its subsidiary LM Capital Solutions, LLC (LMCS). CCUR Holdings has its corporate office in Duluth, Georgia. The Company lists on the OTCQB.

CCUR Holdings earlier announced that through its newly created subsidiary, LM Capital Solutions, LLC (LMCS), it closed on a Purchase Agreement to acquire the operating assets of LuxeMark Capital, LLC. LuxeMark operates by way of its syndication network to facilitate merchant cash advance (MCA) funding through connecting a network of MCA originators with syndicate participants who provide those originators with more capital by purchasing participation interests in funded MCAs. Additionally, LuxeMark Capital uses its expertise in the MCA industry to provide servicing and other administrative services to its syndicate network.

Last week, CCUR Holdings reported Net Income attributable to its stockholders of $803,000, or $0.09 per share, for Q4 of 2019. During the prior year period, CCUR reported a Net Loss of $1,700,000, or ($0.18) per share. Revenue for the quarter grew to $1,846,000 versus $54,000 during the prior year period and $1,074,000 in Q3 of fiscal 2019.

Merchant Cash Advance (MCA) revenue grew to $1,435,000. Revenue from interest on loans increased to $411,000. Other interest, dividend and investment income for the period totaled $1,770,000.

Mr. Wayne Barr, President and Chief Executive Officer of CCUR Holdings, said, “Our fourth-quarter and full-year financial results continue to demonstrate the successful execution of our business plan. The returns from our MCA and real estate operations continued to increase during the quarter and our operating segments are well positioned as we enter fiscal 2020.”

CCUR Holdings, Inc. (CCUR), closed Thursday's trading session at $3.43, up 0.163532%, on 4,221 volume with 10 trades. The average volume for the last 3 months is 3,496 and the stock's 52-week low/high is $3.00/$4.94000005.

chart

Chemesis International, Inc. (CADMF)

Green Stock Report, Small Caps Daily, The Trading Letter, Financial Buzz, Midas Letter, Business Insider, Trading View, GlobeNewswire, Stockwatch, Technical420, Insider Financial, CannabisMarketCap, CannabisFN, OTC Markets, InvestorsHub, Tip Ranks, Market Screener, Stockhouse, Investing News, Canadian Insider, Dividend Investor, and Insider Tracking reported previously on Chemesis International, Inc. (CADMF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Chemesis International, Inc. is a vertically integrated global leader in the cannabis industry. It is currently operating within California, Puerto Rico, and Colombia. The Company is developing a strong presence in important markets. This is from cultivation, to manufacturing, distribution and retail. Chemesis has a worldwide reach and exclusive partnerships. OTCQB-listed, the Company is based in Vancouver, British Columbia.

Chemesis International is working to expand its operations into the Central United States. The Company is concentrating on establishing operations in Michigan, Wisconsin, Missouri, and Illinois.

The Company has facilities in Puerto Rico and California, allowing for the cost effective production and distribution of its products. In addition, the Company leverages exclusive brands and partnerships. Furthermore, Chemesis uses the highest quality extraction methods to provide consumers with first-rate cannabis products.

Chemesis International has current operations underway in Puerto Rico with Natural Ventures, in Colombia with La Finca, and in California with California Sap and Desert Zen. The Company has its state-of-the-art grow facility in Puerto Rico that highlights a 2,000-plus grow light capacity and a 30,000-plus lb overall grow capacity. Chemesis’ Puerto Rico operations are licensed to operate 100,000 ft2 of cultivation, and 35,000 ft2 of manufacturing floor space.

Additionally, La Finca brings more than 1,000 acres of land for cultivation in Colombia. Chemesis has over 2,000 relationships with farming families that comprise its land package.

Regarding Retail Sales, Chemesis International is presently retailing exclusive products in Puerto Rico and engaging retail storefronts in the California marketplace. It is also working to open exclusively branded shops in manifold markets. The Company distributes and transports California Sap, Jay and Silent Bob’s Private Stash, and 3rd party brands to more than 600 dispensaries in California and Puerto Rico.

Concerning Manufacturing, Chemesis International is able to offer it’s clients all types of extractions, formulations and products, specializing in BHO Extraction, Alchohol Extraction, and CO2 Extraction. At present, it has the capacity to process greater than 2,000 lbs of raw material per day.

Pertaining to Distribution, the Company’s Desert Zen currently has a significant presence in Southern California. Chemesis has a fleet of fully compliant vehicles that are servicing the State.

Last week, Chemesis International announced that it completed its earlier announced transaction to acquire a controlling interest in GSRX Industries, Inc. (OTCQB: GSRX). As a result of the Acquisition, GSRX is a subsidiary of Chemesis International and, under IFRS rules, GSRX’s financial position and assets, including its ownership of 7,291,874 earlier-acquired Chemesis International shares will be consolidated with Chemesis on a go-forward basis. Thus, Chemesis has become a fully vertically-integrated, multi-state operator with assets in six States. These include California, Tennessee, Arizona, Michigan, Texas, and Puerto Rico.

Yesterday, Chemesis International announced that its subsidiary, Natural Ventures, completed the installation, permitting, and testing phase of its QuickStrip™ oral thin strip production equipment. The Company completed the earlier announced commercialization strategy. It has started accepting orders for QuickStrip for immediate distribution throughout Puerto Rico and the U.S.

Chemesis International, Inc. (CADMF), closed Thursday's trading session at $0.80036, off by 0.749008%, on 50,969 volume with 71 trades. The average volume for the last 3 months is 194,813 and the stock's 52-week low/high is $0.598999977/$1.72000002.

chart

Columbia Care, Inc. (CCHWF)

Penny Stock Hub, TipRanks, New Cannabis Ventures, The Cannabis Reporter, Stockwatch, TradingView, Biospace, Market Screener, Street Insider, Global Banking and Finance, Wallet Investor, InvestorX, Technical420, and Stockhouse reported beforehand on Columbia Care, Inc. (CCHWF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Columbia Care, Inc. is a vertically integrated medical cannabis company listed on the OTC Markets Group’s OTCQX. The Company has a U.S. license portfolio that allows for up to 730K square feet of cultivation and the potential to produce greater than 125 K kilograms of dried flower per year. Columbia Care is one of the largest and most experienced multi-state operators in the medical cannabis industry. It has licenses in 15 jurisdictions in the United States and the European Union (EU). Established in 2013, Columbia Care is based in New York, New York.

The Company has more than 1,000,000 successful sales transactions since its inception. Columbia Care works together with some of the most renowned and innovative teaching hospitals and medical centers in the world. It has built 14 State-by-State vertically integrated operations, including 54 facilities in operation or development, and 35 licenses in 15 markets.

Columbia Care offers medical cannabis products. In addition, it offers an assortment of health and wellness brands and products. This includes the Company’s own hemp CBD (cannabidiol) brands. These brands are full spectrum, independent 3rd party tested, organic, GMO-free, and produced in cGMP-compliant facilities. Columbia Care’s flagship hemp CBD brand is Columbia Care Platinum Label. The Company’s objective with this brand is to set the standard in potency and purity.

Recently, Columbia Care announced a collaboration with pharmaceutical manufacturer IPS Specials. This agreement will see Columbia Care’s BeneCeed CBD tablets imported into the United Kingdom (UK) for a clinical study. Columbia Care said that this agreement is the initial step in the Company's efforts to hold worldwide clinical trials using its cannabis.

BeneCeed will become the first approved cannabinoid investigational medicinal product imported from the United States by the U.K.’s Medicines and Healthcare products Regulatory Agency. BeneCeed would be used in an examination of a late-stage Phase 2b trial.

Columbia Care, Inc. (CCHWF), closed Thursday's trading session at $4.24041, off by 0.68181%, on 6,230 volume with 21 trades. The average volume for the last 3 months is 12,382 and the stock's 52-week low/high is $3.5999999/$7.19910001.

chart

Great Bear Resources Ltd. (GTBDF)

Proactive Investors, Streetwise Reports, Insidexploration, Stockhouse, Investing News, Metals News, Connecting Investor, Stockwatch, Mining Capital, Junior Mining Network, Wallet Investor, Street Insider, and Market Screener reported earlier on Great Bear Resources Ltd. (GTBDF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

A mineral exploration company, Great Bear Resources Ltd. engages in the acquisition and exploration of mineral properties in Canada. It holds interests in the Dixie property, located about a 15 minutes' drive along Highway 105 from downtown Red Lake, Ontario. The Red Lake mining district has produced more than 30,000,000 ounces of gold. It is one of the premier mining districts in Canada. Incorporated in 2001, Great Bear Resources is based in Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Dixie property encompasses a drill and geophysically defined 10 kilometer gold mineralized structure similar to that hosting other producing gold mines in the district. At the Dixie Project, gold mineralization is confirmed along a 2.3 km strike of a 10 km target. The system at Dixie has a high-grade gold zone. It includes recent intervals of 16.35 meters of 26.91 g/t gold and 7.00 meters of 68.76 g/t gold and is open along strike and at depth.

Furthermore, Great Bear Resources is earning a 100 percent royalty-free interest in the West Madsen, Pakwash, Dedee and Sobel properties. These properties encompass regionally significant gold-controlling structures and prospective geology. The West Madsen project comprises two claims blocks; the easternmost (Block A) is now directly contiguous to Pure Gold Mining’s Madsen property. Each block is about six kilometers by three kilometers in size, for a total area of 3,860 hectares.

Great Bear Resources has reported the discovery of a new gold control within its Dixie Limb Zone (DL) target associated with thickened and higher-grade gold mineralization. The new discovery enhances the DL as a major potential host of high-grade gold. The DL is the original gold discovery at the Dixie project, made by Teck Resources. It is roughly 200 meters to the north of, and is sub-parallel to, Great Bear's 2018 high-grade gold discovery at the Hinge Zone (DHZ).

This week, Great Bear Resources reported numerous gold discoveries along 3.2 kilometers strike length of the roughly 18 kilometer long LP Fault target at its 100 percent owned Dixie project in the Red Lake district of Ontario. Drilling at the new "Auro" Zone, a 2.6 km step-out from Bear-Rimini, intersected 101.71 g/t Gold over 1.50 m within 42.00 m of 5.28 g/t Gold at 80 m depth. The Yuma Zone intercepts include 27.77 g/t Gold over 2.00 m within 11.08 g/t Gold over 7.00 m.

Great Bear Resources Ltd. (GTBDF), closed Thursday's trading session at $5.9658, off by 10.0181%, on 129,662 volume with 289 trades. The average volume for the last 3 months is 40,263 and the stock's 52-week low/high is $1.26179003/$7.09030008.

chart

Peyto Exploration & Development Corp. (PEYUF)

Streetwise Reports, Finance Recorder, Whale Wisdom, Stock2Own, Street Insider, TeleTrader, Dividend Investor, Market Screener, GuruFocus, Stockhouse, Wallet Investor, TradingView, and Morningstar reported earlier on Peyto Exploration & Development Corp. (PEYUF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Peyto Exploration & Development Corp. engages in the exploration, development, and production of oil and natural gas, and natural gas liquids (NGLs) in Deep Basin, Alberta. The Company is the 6th largest natural gas producer in Canada. It owns/operates gas plants and operates 99 percent of production. It has a 99 percent Working Interest (WI) in 9 processing facilities. Peyto lists on the OTC Markets.

The company previously went by the name Peyto Energy Trust. It changed its corporate name to Peyto Exploration & Development Corp. in January of 2011. Incorporated in 1997, the Company is headquartered in Calgary, Alberta.

Peyto Exploration & Development’s gas and NGLs are made from all natural, decomposed, organic materials. The Company’s belief is that by maintaining low cash costs over the entire production life it ensures returns are maximized regardless of commodity price volatility. As of December 31, 2018, Peyto had a total proved plus probable reserves of 803 million barrels of oil equivalent.

The Company’s strategy is to integrate the entire oil and gas value chain. It is working to become an integrated energy business. This includes exploration and development, production and processing, storage and marketing, and midstream and power generation.

Moreover, Peyto’s strategy is to invest for profit, not growth. The Company’s track record of generating $0.40 of earnings for every dollar of capital invested is one of the highest in the industry. It has driven total supply cost down 36 percent in the last five years. This is chiefly through capital cost improvements. This has preserved the Company’s approximately 35 percent profit margin.

Recently, Peyto Exploration & Development confirmed that the monthly dividend with respect to August 2019 of $0.02 per common share is to be paid on September 13, 2019, for shareholders of record on August 31, 2019. The ex-dividend date is August 29, 2019.

Peyto Exploration & Development Corp. (PEYUF), closed Thursday's trading session at $2.50995, up 2.9048%, on 15,818 volume with 26 trades. The average volume for the last 3 months is 29,342 and the stock's 52-week low/high is $2.25/$9.59959983.

chart

Real Goods Solar, Inc. (RGSE)

StockTwits, Zacks, 4-Traders, Investing.com, Insider Tracking, Investors Observer, AIStockFinder, Barchart, GlobeNewswire, Stockhouse, Market Screener, and MacroTrends reported earlier on Real Goods Solar, Inc. (RGSE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Real Goods Solar, Inc. (RGS Energy) is the exclusive worldwide manufacturer of the POWERHOUSE™ Solar Shingle System. This is an inventive in-roof solar shingle employing technology developed by The Dow Chemical Company. The design of POWERHOUSE solar shingles are to integrate with asphalt roofing products. The POWERHOUSE Solar Shingle is a pioneering new roofing tile product that combines the performance and protection of a conventional asphalt roof with an integrated photovoltaic (PV) system that powers a home. Real Goods Solar has its head office in Denver, Colorado. The Company’s shares trade on the OTC Markets Group’s OTCQX.

RGS Energy (RGSE) is exiting its mainland residential solar business to focus on the POWERHOUSE™ in-roof shingle market. The Company is concentrating its efforts and resources on what it believes is a significant opportunity with its POWERHOUSE™ solar shingle. This is because of the State of California’s mandate that all new homes built in 2020 include a solar installation. POWERHOUSE™ is a trademark of The Dow Chemical Company, used under license.

RGSE believes the POWERHOUSE™ solar shingle has compelling competitive advantages. These include an aesthetically appealing low profile, with power efficiency and cost competitive to traditional rack-n-mount solar.

The POWERHOUSE 3.0 Solar Shingles operate as a roof and solar product. They are installed directly onto the roof deck along with standard asphalt roofing shingles. The design of POWERHOUSE 3.0 is to achieve a competitive price point for Roofers; Homebuilders; Homeowners; as well as Solar Installers.

Recently, RGSE announced that it joined Builder Partnerships network to offer POWERHOUSE™ to their more than 1,400 builder members. Builder Partnerships network is an innovative networking organization. It supports top regional builders and manufacturers as they compete and thrive in today’s competitive environment. Builder Partnerships helps their members generate premier returns, establish strategic relationships, and enhance management practices.

Real Goods Solar, Inc. (RGSE), closed Thursday's trading session at $0.145, up 1.3986%, on 353,608 volume with 95 trades. The average volume for the last 3 months is 1,114,668 and the stock's 52-week low/high is $0.064000003/$0.884000003.

chart

Patriot Gold Corp. (PGOL)

Investopedia, The Street, Proactive Investors, Stockwatch, Barchart, Dividend Investor, YCharts, Wallet Investor, Real Pennies, OtcWizard, Standout Stocks, Marketwired, and Gold Investment Letter reported beforehand on Patriot Gold Corp. (PGOL), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Patriot Gold Corp. is a precious metals exploration and production company listed on the OTC Markets’ OTCQB. Its mission is to discover and develop significant gold and silver assets in Arizona and Nevada. Currently, the Company holds a portfolio of four projects. These are the Moss project in Arizona and three in Nevada (Bruner, Vernal, and Windy Peak). Patriot Gold is based in Las Vegas, Nevada.

The Company holds a 3 percent royalty in the Moss Mine in Arizona, an interest in the Bruner gold project in Nevada, and a 100 percent interest in the Windy Peak and Vernal projects in Nevada. The Moss Mine Project is within the historic Oatman District, 10 miles east of Bullhead City, Arizona and roughly 70 miles southeast of Las Vegas. Northern Vertex Mining Corp. is the owner of the Moss Mine. The Moss Mine entered commercial production as of the beginning of September 2018.

The Vernal gold project is in its early stage. This property is approximately 140 miles east-southeast of Reno, Nevada, on the west side of the Shoshone Mountains. This property comprises 12 unpatented mining claims (240 acres).

The Windy Peak Gold Project comprises 79 unpatented mineral claims in the Fairview mining district in southwest Nevada. Windy Peak is easily accessed. It is about 45 miles southeast of Fallon and 6 miles from Middlegate.

Patriot Gold owns a 2 percent royalty in the Bruner gold project. The Bruner gold project property is approximately 130 miles east-southeast of Reno, Nevada. It is at the northern end of the Paradise Range and 45 miles northwest of the Round Mountain Mine. Canamex Resources Corp. is the owner of the Bruner gold project.

The Bruner and Vernal gold projects are in Nevada's Walker Lane, which hosts many major deposits. These include the Goldfield (more than 5 million ounces of post production and current reserves) and the Comstock (more than 8 million ounces).

Recently, Patriot Gold announced that it completed an initial phase of drilling exploration at the Windy Peak Project in Churchill County, Nevada, beginning in September 2018. At present, the Windy Peak deposit is interpreted as a low-sulfidation, epithermal gold deposit positioned marginal to and likely associated with a caldera ring fracture zone.

Intersections between ring fractures and regional normal faults in the Windy Peak Project area are especially favorable exploration targets. They offer the unique combination of fluid conduits and structural controls known to concentrate high-grade mineralization.

Patriot Gold Corp. (PGOL), closed Thursday's trading session at $0.0625, up 22.549%, on 150,045 volume with 7 trades. The average volume for the last 3 months is 15,155 and the stock's 52-week low/high is $0.0412/$0.150000005.

chart

Nippon Dragon Resources, Inc. (RCCMF)

OTC Markets Group, InvestorsHub, MarketWatch, Investor Place, Stock Gumshoe, Zacks, Dividend Investor, Morningstar, Talk Markets, Streetwise Reports, 4-Traders, Wallet Investor, GuruFoucs, YCharts, and Stockhouse reported previously on Nippon Dragon Resources, Inc. (RCCMF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Nippon Dragon Resources, Inc. is a hybrid mining & technology enterprise listed on the OTC Markets. The Company has high potential and advanced stage mining assets combined with an innovative and exclusive green mining method. Nippon is active in the exploration and development of gold resources in the Province of Quebec. Nippon’s flagship gold property is Rocmec 1. Nippon Dragon Resources is headquartered in Brossard, Quebec.

The Company has its Thermal Fragmentation mining method. This mining method uses heat to 'spall' high-grade veins. This considerably lessens the use of explosives. The method only extracts the mineralized ore with minimal dilution. The extraction process allows thermal fragmentation with an accuracy of 2 cm to quickly extract any type of hard rock up to 110 cm wide. The thermal unit can be set up to extract a specific corridor. Thermal Fragmentation could be used as a stand-alone method or as a first-rate complement to any conventional hard rock mining operation.

In June of last year, Nippon Dragon Resources announced that following the sale of a Thermal Fragmentation Unit to its client, Metalfer Mining D.O.O, the Unit was shipped, received, inspected by border authorities and released to the client. Nippon’s technical team performed its customary four week orientation, training, and implementation programme of its thermal fragmentation mining method at Metalfer’s mining site in the Majdan Mountain district of Serbia.

Nippon Dragon Resources has a strategic partnership agreement with Val d’Or Resources (VOR). This partnership agreement will enhance Nippon Dragon’s position as an industry leader with its exclusive and patented Thermal Fragmentation technology. Through the creation of a new entity, Rocmec Gold, Inc., the new partnership is anticipated to substantially expand Nippon Dragon’s reach within Canada and other important markets.

Nippon’s flagship Rocmec 1 is a fully permitted project in Quebec. The project includes a 100-meter deep, two-compartment shaft, and an 844 meters decline, allowing access to four levels (50, 90, 110 and 130 meters).

Additionally, Nippon has its Denain Project. This project covers two contiguous mining properties (Venpar and Vauquelin) totaling 24 mining titles. The Denain Project is about 60 km east of Val d'Or, Quebec. At the end of August 2018, Nippon Dragon Resources announced that it signed a joint venture (JV) agreement with a group of private investors to develop its Denain gold property.

In addition, Nippon has its Courville-Maruska exploration property in Courville Township, roughly 32 kilometers’ northeast of Val-d'Or, Quebec. The property consists of 20 mining claims covering an area of around 800 hectares. The property is on a gold-bearing quartz vein system.

Nippon Dragon Resources, Inc. (RCCMF), closed Thursday's trading session at $0.012, up 33.3333%, on 7,175 volume with 3 trades. The average volume for the last 3 months is 3,691 and the stock's 52-week low/high is $0.002/$0.024599999.

chart

FISION Corp. (FSSN)

NetworkNewsWire, Penny Stock Tweets, Stockhouse, InvestorsHub, InvestorPoint, The Street, Wallet Investor, Market Screener, OTC Markets, Stockwatch, Dividend Investor, Investing, YCharts, Barchart, TradingView, MarketWatch, Business Wire, GuruFocus, and Capital Market Access reported earlier on FISION Corp. (FSSN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

FISION Corp. is a cloud-based digital asset management and marketing automation company. It serves  enterprise clients in the healthcare, hospitality, financial/insurance, software, and technology industries. The Company is an effective sales enablement and marketing asset management tool. Established in 2011 and OTCQB-listed, FISION is based in Minneapolis, Minnesota.

FISION maximizes the brand potential of every sales interaction. The Company’s advanced, proprietary technology specializes in managing customers’ brand and marketing content. This enables marketing and sales people to quickly and easily create compelling, personalized, on-brand communications that increase revenue and profits.

FISION equips marketing and sales teams with a wide-ranging  set of enablement capabilities built to solve distributed marketing challenges. FISION’s solutions include simplified brand distribution, sales enablement, distributed & localized marketing, digital asset management, channel support, and measurement & analytics. FISION’s centralized, cloud-based library supports manifold different file types. It gives a client complete control over how company assets are stored, retrieved, and used.

FISION completed the acquisition of Volerro Corporation (Minneapolis, Minnesota-based) following the announcement of a definitive purchase agreement on April 25, 2017. Volerro is a leader in cloud-based content collaboration and agile marketing technology. Volerro enhances the FISION platform with complementary cloud-based collaboration, agile marketing, and sales enablement software.  Volerro’s ReVu.Me cloud app allows team members to work on the same document in real-time with integrated chat and voice conferencing.

In August 2018, FISION announced a merger agreement with Continuity Logic LLC. FISION's "front of the house" sales and marketing solution is complemented by Continuity Logic's "back of the house" enterprise integration & user-friendly application interface. This agreement in 2018 allowed both companies to immediately take advantage of each others customer base and sales pipeline, with no current overlapping of clients.

In October 2018, FISION announced it was named the #1 software company in Minnesota by Twin Cities Business (TBC) magazine. FISION is the category winner in the publication’s 2018 Best of Business Reader’s Choice Awards. FISION currently has greater than 65,000 users across 21 countries.

FISION Corp. (FSSN), closed Thursday's trading session at $0.024, up 20.00%, on 137,000 volume with 7 trades. The average volume for the last 3 months is 57,774 and the stock's 52-week low/high is $0.014999999/$0.219999998.

chart

Wize Pharma, Inc. (WIZP)

Dividend Investor, Stockwatch, Capital Cube, Cardinal Weekly, Investors Hangout, Insider Mole, Stockopedia, Penny Stock Hub, Stockhouse, InvestorsHub, Wallmine, OTC Markets, Barchart, MarketWatch, and 4-Traders reported earlier on Wize Pharma, Inc. (WIZP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Wize Pharma, Inc. focuses on the treatment of ophthalmic disorders. This includes dry eye syndrome (DES). The OTCQB-listed Company previously went by the name Star Night Technologies Ltd. It changed its corporate name to Wize Pharma, Inc. in July of 2015. A clinical-stage biopharmaceutical enterprise, the Company is headquartered in Hod Hasharon, Israel.

Wize Pharma has in-licensed certain rights to purchase, market, sell, and distribute a formula named LO2A. This is a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis (CCH) and Sjögren's Syndrome. Currently, LO2A is registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH, and in the Netherlands for the treatment of DES and Sjögren's Syndrome.

Wize Pharma is now conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study for LO2A for DES in patients with Sjögren's. The Company announced in March of last year that it enrolled the initial patient in its Phase IV clinical trial in Israel for LO2A in the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome. This randomized, double-masked study is evaluating LO2A versus Alcon's Systane® Ultra UD, an over-the-counter (OTC) lubricant eye drop product used to relieve dry and irritated eyes.

The design of the study (in addition to meeting marketing approval requirements in Israel) is to support Wize Pharma’s clinical approval pathway for LO2A for the treatment of DES in patients with Sjögren's in other markets including the U.S., China, and Ukraine. LO2A is already approved in Israel for the treatment of DES.

This past November, Wize Pharma announced top line results from its Phase II clinical trial in Israel of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with moderate to severe conjunctivochalasis (CCh). Wize Pharma's Chairman, Noam Danenberg, stated, "We are very pleased with these top line results and we look forward to analyzing the full results. We believe the full results from this study, will support our clinical development path and provide firm basis for presentation and discussions with the FDA for the approval pathway of LO2A in the U.S. and additional countries."

Recently, Wize Pharma announced that it signed an agreement with Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) to form a joint venture (JV) company for researching, developing and administering cannabinoid formulations to treat ophthalmic conditions. Cannabics Pharmaceuticals is a global leader in personalized cannabinoid medicine centered on cancer and its side effects.

This agreement will become effective subject to receipt of an expert opinion, within 30 days from the date of signing, describing the regulatory pathway for eye drops containing cannabinoids. Upon effectiveness, Wize Pharma shall issue 900,000 shares of its common stock to Cannabics Pharmaceuticals. Cannabics shall issue 2,263,944 shares of its common stock to Wize. This agreement will expire if the parties have not approved a business plan by June 30, 2019.

Wize Pharma, Inc. (WIZP), closed Thursday's trading session at $0.2807, up 7.9615%, on 4,795 volume with 4 trades. The average volume for the last 3 months is 14,875 and the stock's 52-week low/high is $0.100000001/$3.42000007.

chart

Esports Entertainment Group, Inc.  (GMBL)

Stockrow, Real Pennies, Dividend Investor, Proactive Investors, Capital Network, Infront Analytics, YCharts, OTC Markets, RedChip, Marketbeat, TradingView, Capital Cube, and Wallet Investor reported earlier on Esports Entertainment Group, Inc. (GMBL), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

Esports Entertainment Group, Inc. is a next generation, licensed, online gambling business especially focused on esports wagering. Its plan is to offer wagering on esports events in a fully licensed, regulated, and secured platform to the global esports audience, excluding the United States. Esports Entertainment Group has offices in St. Mary's, Antigua, and Barbuda.

Last week, Esports Entertainment Group announced the hiring of two key executives and the opening of its new international headquarters in Malta. Malta was selected because of its strategic location within the European Union (EU), and also access to a highly educated and multi-lingual workforce, particularly in the fields of online gambling.

The Company’s plan is to offer users around the world the ability to participate in multi-player video games tournaments online for cash prizes. At present, the Company is developing several play money websites and its real money wagering website.  

Esports Entertainment is a licensed online gambling business with a particular emphasis on esports wagering and 18+ gaming. The Company’s online esports gambling platform will be completely licensed and the highest regulated esports gambling site worldwide.

The Company has been issued a Client Provider Authorization Permit by the Kahnawake Gaming Commission. Esports has applied for an Interactive Wagering License with the Financial Services Regulatory Commission of Antigua and Barbuda to conduct real money interactive gaming on a worldwide basis from centers in Canada and Antigua.

Esports Entertainment has an agreement with PartnerMatrix. This is the first platform that enables online sportsbook and casino operators to run Affiliate System with Agent functionality and Agent System with Affiliate functionality. With the agreement, Esports Entertainment Group will integrate the PartnerMatrix platform to manage its affiliate program on an expedited basis. Esports Entertainment Group has also launched vie.gg. This is the world’s first and most transparent esports betting exchange.

Recently, Esports Entertainment Group announced Affiliate Marketing Agreements with 14 more esports teams as it continues to ramp up affiliate marketing activities in support of its launch of vie.gg. The addition of these 14 esports teams brings the total number of esports team affiliates to 190 since the Company’s first announcement on April 5, 2018.

Esports Entertainment Group, Inc. (GMBL), closed Thursday's trading session at $0.455, up 30.00%, on 25,075 volume with 15 trades. The average volume for the last 3 months is 17,635 and the stock's 52-week low/high is $0.263999998/$0.973999977.

chart

Explor Resources, Inc. (EXSFF)

Streetwise Reports, Vantage Wire, Stockhouse, and InvestorsHub reported earlier on Explor Resources, Inc. (EXSFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Explor Resources, Inc. is a natural resources company headquartered in Rouyn-Noranda, Quebec.  The Company has mineral holdings in Ontario, Quebec, Saskatchewan and New Brunswick. Its Flagship project is the Timmins Porcupine West (TPW) Project situated in the Porcupine mining camp in Ontario. A gold and base metals exploration company,  Explor Resources lists on the OTC Markets Group’s OTCQB.

The Company is presently concentrating on exploration in the Abitibi Greenstone Belt. This belt is in both provinces of Ontario and Quebec - roughly 33 percent in Ontario and 67 percent in Quebec.  Explor’s total land position in the Abitibi Greenstone Belt is about  25,000 hectares. In addition, Explor owns 6,500 hectares of mining claims in New Brunswick.

Abitibi Greenstone Belt properties 100 percent-owned by the Company in Ontario include Carnegie, Kidd Township, Eastford Lake, PG-101, Montrose, Golden Harker, Timmins Porcupine West, and Ogden. Abitibi Greenstone Belt properties 100 percent-owned by Explor Resources in Quebec include East Bay, Nelligan, Destor, and Launay. 

Explor Resources has signed a Memorandum of Understanding (MOU) with the Matachewan First Nation of Matachewan, Ontario and the Mattagami First Nation of Gogama, Ontario, concerning the Montrose Property. The MOU will serve as a structure to govern the relationship between Explor Resources and the First Nations in accordance with their intention of further building a relationship characterized by cooperation and mutual respect, in connection with the development of the Montrose Property.

The Montrose property consists of 20 mining claims (217 units) positioned in the Montrose and Midlothian Townships in the Timmins-Porcupine Mining Camp for a total of around 3,472 hectares.

In December 2017, Explor Resources announced the acquisition of two mining claims (3 units) located in Ogden Township, in the Porcupine Mining Division, District of Cochrane, Ontario for a total of 48.56 hectares. The claims are in Ogden Township contiguous and to the east of the Timmins Porcupine West Gold Property.

The claims were acquired because of encouraging results obtained in the Company's past exploration on the property. Explor Resources will pay CDN $2,000 and issue 100,000 common shares to obtain a 100 percent interest in the additional Ogden mining claims. The Optionors have retained a 2 percent NSR (Net Smelter Return) in the property.

Recently, Explor Resources announced the results of the East Bay Gold Property exploration program. The analysis of earlier exploration by Cambior and the results of the previous exploration program completed by Explor Resources confirmed a number of interesting drill targets. The exploration program comprised a Phase III 3000 meter drill program.

The East Bay Gold Property is positioned to the west of the Consolidated Beattie and Donchester Gold Property. It is contiguous to the ground on which the former Clifton Star Resources, Inc. intersected wide width of gold mineralization.

Furthermore, Explor Resources announced recently the acquisition of eight mining claims (64 claim units) located in Hoyle Township, in the Porcupine Mining Division, District of Cochrane, Ontario for a total of 1036.4 hectares. The claims are positioned in Hoyle Township, north of Bell Creek, Owl Creek and Hoyle Pond gold Mines.

The claims were obtained because of results attained by Tahoe Resources and Goldcorp in their exploration programs in Hoyle Township. Explor Resources will pay CDN $1,000 and issue 3,000,000 common shares to obtain a 100 percent interest in the property.

Explor Resources, Inc. (EXSFF), closed Thursday's trading session at $0.0255, up 21.4286%, on 10,399 volume with 4 trades. The average volume for the last 3 months is 23,218 and the stock's 52-week low/high is $0.006699999/$0.028999999.

chart

Vycor Medical, Inc. (VYCO)

PennyStockScholar, FeedBlitz, OTCtipReporter, and Wall Street Resources reported earlier on Vycor Medical, Inc. (VYCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Vycor Medical, Inc. is a provider of distinct and first-class surgical and therapeutic solutions. The Company operates two business units - Vycor Medical and NovaVision. Both of these business units adopt a minimally or non-invasive approach. Vycor Medical has U.S. Food and Drug Administration (FDA) 510(k) clearance for brain and spine surgeries and regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU – Class III), Korea, Japan, Russia, and Taiwan. Vycor Medical is based in Boca Raton, Florida.

The Company’s NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight because of stroke or brain injury. The NovaVision business unit develops and provides science-driven neurostimulation therapy and other medical technologies. This helps improve and partially restore sight in patients with neurological vision impairments.

Vycor Medical’s ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices. These have the potential for quicker, safer, and also more economical brain surgeries, as well as faster patient discharge.

The design of VBAS is to optimize neurosurgical site access and reduce patient risk. In addition, the design of VBAS is to expedite recovery and add tangible value to the professional medical community.

The Company’s proprietary Visual Restoration Therapy® (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury (TBI), or other acquired brain injuries. VRT is the only FDA 510K cleared medical device in the United States targeted at the restoration of vision for neurologically induced vision loss.

Vycor Medical has developed NeuroEyeCoach™. This is a therapy that is highly complementary to VRT™. NeuroEyeCoach™ is a compensation therapy registered in the United States as a Class I 510(k) exempt device. The design of NeuroEyeCoach is to improve a patient's ability to scan their environment more efficiently. NeuroEyeCoach is NovaVision's eye movement compensation therapy for patients who have suffered a cerebral visual field disorder due to a stroke or brain injury.

Recently, Vycor Medical reported financial results for the three and six months ended June 30, 2017. The Company’s Revenues for the six months ended June 30, 2017 were $736,000 versus $779,000 for the same period the year prior. Cash Operating Loss was $235,000, versus $329,000 for the same period in 2016. This represents a reduction of 29 percent. Operating Loss was $654,000, versus $806,000. This represents a reduction of 19 percent.

During the period, the US patent office (USPTO) issued/allowed four patents. These are all directed to the integration of neuro-navigation systems with Vycor Medical's VBAS retractor system.

The patents complement and strengthen the Company’s existing patent portfolio. This is especially in relation to Vycor’s continuing emphasis to more fully integrate its VBAS product range with neuro-navigation systems without sacrificing the surgeon's ability to visually inspect the surrounding tissue as the devices undergo insertion.

Vycor Medical, Inc. (VYCO), closed Thursday's trading session at $0.137736, up 20.8211%, on 100 volume with 1 trade. The average volume for the last 3 months is 4,685 and the stock's 52-week low/high is $0.032099999/$0.349999994.

chart

The QualityStocks Company Corner

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), a company dedicated to producing organic cannabis using craft farming techniques, was one of the presenters at the Cannabis Investor Conference held by New West Partners on August 22, 2019, in San Francisco, California (http://nnw.fm/YY6Mv). Based in Hamilton, Ontario, The Green Organic Dutchman is committed to become a global leader in the delivery of premium-quality cannabis in compliance with the provisions of ACMPR and the Controlled Drugs and Substances Act (Canada).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Thursday's trading session at $2.24, up 0.900901%, on 958,472 volume with 1,065 trades. The average volume for the last 3 months is 560,668 and the stock's 52-week low/high is $1.60699999/$7.89379978.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) ("GGB" or the "Company") announced today it has issued an aggregate of 1,127,543 units ("Compensation Units") at a price of $2.45 per Unit in satisfaction of a portion of the cash commission payable to the syndicate of underwriters of Company's recently completed $50.2 million prospectus offering (the "Offering") of units of the Company.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed Thursday's trading session at $1.2812, up 1.6825%, on 170,761 volume with 315 trades. The average volume for the last 3 months is 405,064 and the stock's 52-week low/high is $1.12569999/$5.20499992.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) and how the company is penetrating the European cannabis market with the launch of Supreme Heights. Also today, the company was highlighted in a publication from Motley Fool, examining how Canada officially legalized dried cannabis flower, oils, and sprays for recreational use last year. However, there were many other marijuana products left off the table. Most notably excluded were cannabinoid-based edibles, beverages, topicals, and concentrates. Additionally, the company was featured today in the 420 with CNW by CannabisNewsWire.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Thursday's trading session at $1.05, up 1.9417%, on 480,637 volume with 367 trades. The average volume for the last 3 months is 384,050 and the stock's 52-week low/high is $0.850000023/$2.03999996.

Recent News

chart

HTC Extraction Systems (TSX.V: HTC)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC).

HTC Extraction Systems (TSX.V: HTC) has developed and optimized proprietary extraction and purification systems for biomass, gas and liquid extraction. To view the full article, visit: http://nnw.fm/m9vvR.

HTC Extraction Systems (TSX.V: HTC) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

  • LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
  • PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
  • Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

  • Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
  • Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
  • Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (TSX.V: HTC), closed Thursday's trading session at $0.71, up 1.4286%, on 142,150 volume with 23 trades. The average volume for the last 3 months is 233,220 and the stock's 52-week low/high is $0.079999998/$1.24.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech’s (OTCQB: ETST) wholly owned subsidiary Earth Science Pharma Inc. is dedicated to research, with a goal of eradicating sexually transmitted infections (“STIs”). To view the full article, visit: http://nnw.fm/NWe0C.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed Thursday's trading session at $0.6955, up 0.50578%, on 13,454 volume with 18 trades. The average volume for the last 3 months is 62,448 and the stock's 52-week low/high is $0.300999999/$2.45000004.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full publication, titled “Innovative Drug-Delivery Systems Benefit Patients and Businesses,” visit: http://nnw.fm/4P2sn.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hmep-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Thursday's trading session at $0.68, up 5.4264%, on 73,457 volume with 80 trades. The average volume for the last 3 months is 74,945 and the stock's 52-week low/high is $0.600000023/$2.20000004.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) continues its expansion of retail, online sales and production capacity in both Canada and the United States, building on its strategic goal of becoming a global wellness leader. Its recent acquisition of City Cannabis Corp., which currently serves the Vancouver, British Columbia, cannabis market, included four retail cannabis stores and the renovation of additional retail locations.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed Thursday's trading session at $0.33, up 5.1816%, on 10,303 volume with 12 trades. The average volume for the last 3 months is 15,745 and the stock's 52-week low/high is $0.250999987/$1.12999999.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile Inc. (TSX-V:SIM / OTCQX:SYATF) is pleased to announce that it has won an initial $200,000 contract to supply its Uniden(R) UV350 in-vehicle smartphones to one of Canada’s largest heavy civil construction companies. The company will begin delivering from Q3 and expects additional orders in the coming quarters from this customer.

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed Thursday's trading session at $0.327, up 2.9921%, on 13,255 volume with 11 trades. The average volume for the last 3 months is 53,560 and the stock's 52-week low/high is $0.288599997/$0.446249991.

Recent News

chart

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy Inc. (TSXV:PQE; OTC:PQEFF; FSE: PQCF), a fully integrated surface oil sands mining oil company with patented - proprietary technology‎, is pleased to announce further progress resulting from the recent plant re-engineering project designed to bring production back online.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed Thursday's trading session at $0.2058, up 0.887298%, on 163,409 volume with 42 trades. The average volume for the last 3 months is 221,945 and the stock's 52-week low/high is $0.112099997/$1.21765995.

Recent News

chart

Marijuana Company of America Inc. (MCOAD)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOAD).

Marijuana Company of America (OTCQB: MCOA, MCOAD), an innovative hemp and cannabis corporation, today announced that the company began trading on a split-adjusted basis, on September 3, 2019.  The Company announced its proposal for a 1-for-60 reverse stock split, on July 31, 2019. The common shares of the Company, which previously traded under the ticker symbol “MCOA,” began trading on a post-split basis under the symbol “MCOAD,” which will continue for a period of 20 business days after which time the “D” will be removed, and the symbol will revert back to “MCOA.” 

Marijuana Company of America Inc. (OTC: MCOAD) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOAD), closed Thursday's trading session at $0.26, even for the day, on 363,383 volume with 334 trades. The average volume for the last 3 months is 801,000 and the stock's 52-week low/high is $0.023/$2.13000011.

Recent News

chart

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)

The QualityStocks Daily Newsletter would like to spotlight Therma Bright, Inc. (OTC: THRBF).

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) ("Therma" or the "Company"), a progressive medical device technology company, today announces that the TherOZap™ technology under the Company's former name, The Jenex Corporation, has filed an international patent application under the PCT convention for its thermal therapy TherOZap™ and has recently entered the national phases in the US, Europe and Canada. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Barely a month before the deadline given by the Mexican Supreme Court compelling the government to pass legalization legalizing marijuana elapses, a senator has filed a bill to end prohibition.

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

Products

The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.

Cannabis

Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.

Management

Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

Therma Bright, Inc. (OTC: THRBF), closed Thursday's trading session at $0.022, even for the day, on 10,000 volume. The average volume for the last 3 months is 153 and the stock's 52-week low/high is $0.009899999/$0.028999999.

Recent News

chart

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to announce that R.J. Tesi, M.D., the Company’s Co-founder and CEO, is scheduled to present at the H.C. Wainwright 21st Annual Healthcare Conference in New York City to introduce the NeuLiv™ program for treatment of NASH. Live webcast: https://inmunebio.com/index.php/en/investors-2/ir-events Date: Tuesday, September 10, 2019
Time: 2:10 p.m. – 2:35 p.m. Eastern Time

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed Thursday's trading session at $6.29, off by 2.1773%, on 29,430 volume with 129 trades. The average volume for the last 3 months is 25,867 and the stock's 52-week low/high is $5.05999994/$11.50.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) (the “Company” or “PLUS”), a leading cannabis branded products company in California, today announced that the Company will be hosting a launch event in New York City. The event will take place on Tuesday, September 17th 2019.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Thursday's trading session at $3.1428, off by 3.355%, on 19,405 volume with 37 trades. The average volume for the last 3 months is 37,872 and the stock's 52-week low/high is $2.51999998/$6.00810003.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. To view the full press releases, visit: http://nnw.fm/AoZ8Q and http://nnw.fm/HIRm0. Also today, NetworkNewsWire released a report on the company detailing how, despite huge public awareness and a decrease in smoking, lung cancer remains one of the most common types of cancer and is a major killer in many countries. An estimated 2.09 million people were affected by lung cancer worldwide in 2018, and 1.76 million of them died. While prevention has improved, survival rates remain low once the disease takes root. To view the full publication, titled “Gene Therapy Treatments Offer Hope for Cancer Patients,” visit: http://nnw.fm/k9gI7.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Thursday's trading session at $0.87, off by 3.3333%, on 9,957 volume with 54 trades. The average volume for the last 3 months is 40,720 and the stock's 52-week low/high is $0.640999972/$2.55999994.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.